MSC2364447C Phase 1b in Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2016-10-04
Target enrollment:
Participant gender:
Summary
The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to
evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C
administered for 4 weeks in systemic lupus erythematosus subjects (SLE).